Loading...

PE anti-mouse CD274 (B7-H1, PD-L1) Antibody PE anti-mouse CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_PE_030308
C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
  • 10Fdot9G2_PE_030308
    C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
124307 25 µg DKK393
Check Availability


Need larger quantities of this item?
Request Bulk Quote
124308 100 µg DKK1147
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  2. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  3. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  4. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  5. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  6. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  7. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  8. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  9. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  10. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  11. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  12. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  13. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  14. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  15. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  16. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  17. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  18. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  19. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  20. Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed
  21. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  22. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  23. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  24. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  25. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  26. Shi J, et al. 2018. Immunity. 49:264. PubMed
  27. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  28. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  29. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  30. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  31. Lu SX, et al. 2021. Cell. . PubMed
  32. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  33. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  34. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  35. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  36. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  37. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  38. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  39. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  40. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  41. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  42. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  43. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  44. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  45. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  46. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  47. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  48. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  49. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  50. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  51. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  52. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  53. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  54. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  55. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  56. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  57. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  58. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  59. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  60. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  61. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  62. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  63. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  64. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  65. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  66. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  67. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  68. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  69. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  70. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  71. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  72. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  73. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  74. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  75. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  76. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  77. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  78. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  79. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  80. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  81. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  82. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  83. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  84. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  85. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  86. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  87. Zheng Y, et al. 2022. Transl Res. :. PubMed
  88. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  89. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  90. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  91. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  92. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  93. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  94. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  95. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  96. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
  97. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  98. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  99. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  100. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  101. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  102. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  103. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  104. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  105. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  106. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  107. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  108. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  109. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  110. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  111. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  112. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  113. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  114. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  115. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  116. Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed
  117. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  118. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  119. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  120. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  121. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  122. Shi J, et al. 2018. Immunity. 49:264. PubMed
  123. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  124. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  125. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  126. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  127. Lu SX, et al. 2021. Cell. . PubMed
  128. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  129. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  130. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  131. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  132. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  133. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  134. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  135. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  136. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  137. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  138. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  139. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  140. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  141. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  142. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  143. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  144. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  145. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  146. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  147. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  148. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  149. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  150. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  151. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  152. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  153. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  154. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  155. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  156. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  157. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  158. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  159. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  160. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  161. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  162. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  163. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  164. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  165. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  166. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  167. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  168. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  169. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  170. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  171. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  172. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  173. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  174. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  175. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  176. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  177. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  178. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  179. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  180. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  181. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  182. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  183. Zheng Y, et al. 2022. Transl Res. :. PubMed
  184. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  185. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  186. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  187. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  188. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  189. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  190. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  191. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  192. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
RRID
AB_2073557 (BioLegend Cat. No. 124307)
AB_2073556 (BioLegend Cat. No. 124308)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/22/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_PE_030308
C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
  • 10Fdot9G2_PE_030308
    C57/B6 mouse splenocytes were stained with anti-CD274 (clone 10F.9G2) PE (filled histogram) or rat IgG2b, κ PE (open histogram).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
124307 25 µg DKK393
Check Availability


Need larger quantities of this item?
Request Bulk Quote
124308 100 µg DKK1147
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  2. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  3. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  4. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  5. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  6. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  7. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  8. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  9. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  10. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  11. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  12. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  13. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  14. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  15. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  16. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  17. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  18. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  19. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  20. Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed
  21. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  22. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  23. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  24. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  25. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  26. Shi J, et al. 2018. Immunity. 49:264. PubMed
  27. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  28. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  29. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  30. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  31. Lu SX, et al. 2021. Cell. . PubMed
  32. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  33. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  34. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  35. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  36. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  37. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  38. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  39. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  40. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  41. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  42. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  43. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  44. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  45. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  46. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  47. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  48. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  49. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  50. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  51. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  52. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  53. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  54. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  55. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  56. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  57. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  58. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  59. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  60. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  61. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  62. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  63. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  64. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  65. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  66. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  67. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  68. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  69. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  70. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  71. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  72. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  73. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  74. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  75. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  76. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  77. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  78. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  79. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  80. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  81. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  82. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  83. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  84. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  85. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  86. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  87. Zheng Y, et al. 2022. Transl Res. :. PubMed
  88. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  89. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  90. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  91. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  92. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  93. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  94. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  95. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  96. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
  97. Sandu I, et al. 2020. Nat Commun. 11:4454. PubMed
  98. Nesseler JP, et al. 2020. Cancers (Basel). 12: . PubMed
  99. Taranto D, et al. 2021. Curr Protoc. 1:e147. PubMed
  100. Xin B, et al. 2022. Hepatology. 76:630. PubMed
  101. Wang W, et al. 2022. Mol Cancer Res. 20:1137. PubMed
  102. Sun Y, et al. 2023. Bioact Mater. 22:47. PubMed
  103. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  104. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  105. Yang Z, et al. 2022. J Nucl Med. 63:1708. PubMed
  106. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  107. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  108. Pi C, et al. 2022. Cancers (Basel). 14:. PubMed
  109. Barsheshet Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  110. Ou W, et al. 2023. Nat Commun. 14:392. PubMed
  111. Spitzer D, et al. 2023. Nat Protoc. 18:1510. PubMed
  112. Yi J, et al. 2023. Nat Commun. 14:1941. PubMed
  113. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  114. Ji Y, et al. 2023. Nat Cell Biol. 25:726. PubMed
  115. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  116. Liu Z, et al. 2023. Front Pharmacol. 14:1154392. PubMed
  117. Mulder R, et al. 2017. Front Immunol. 1.464583333. PubMed
  118. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  119. Fitzgerald B, et al. 2021. Cell Rep Methods. 1:. PubMed
  120. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  121. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  122. Shi J, et al. 2018. Immunity. 49:264. PubMed
  123. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  124. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  125. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  126. Yang M, et al. 2020. Appl Environ Microbiol. 86:00:00. PubMed
  127. Lu SX, et al. 2021. Cell. . PubMed
  128. Jansen MAA, et al. 2019. Front Immunol. 1.852777778. PubMed
  129. Zhang C, et al. 2021. Clin Transl Immunology. 10:e1310. PubMed
  130. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  131. Dichtl S, et al. 2021. Sci Adv. 7: . PubMed
  132. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  133. Vackova J, et al. 2020. Int J Mol Sci. 21:00. PubMed
  134. Zhang S, et al. 2019. Mol Med Rep. 19:5377. PubMed
  135. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  136. Pauken KE, et al. 2020. Cell Reports. 31(13):107827. PubMed
  137. Shen Y, et al. 2022. CNS Neurosci Ther. 28:46. PubMed
  138. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  139. Guo Q, et al. 2022. Nat Commun. 13:3837. PubMed
  140. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  141. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  142. Zhu XG, et al. 2020. Cell Metabolism. 33(1):211-221.e6. PubMed
  143. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  144. Ramos RN, et al. 2022. Clin Transl Immunology. 11:e1392. PubMed
  145. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  146. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  147. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  148. Sheng W et al. 2018. Cell. 174(3):549-563 . PubMed
  149. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  150. Takano T, et al. 2020. Front Immunol. 11:1555. PubMed
  151. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  152. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  153. van Oostrum M, et al. 2019. Nat Commun. 4.398611111. PubMed
  154. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  155. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  156. Shen JZ, et al. 2020. Cell. 184(2):352-369.e23. PubMed
  157. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
  158. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  159. Lastwika K, et al. 2016. Cancer Res . 76: 227 - 238. PubMed
  160. Kriegsman BA, et al. 2019. J Immunol. 203:1999. PubMed
  161. Dimitrov V, et al. 2017. J Biol Chem. 292:20657. PubMed
  162. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  163. Ou YC, et al. 2020. ACS Nano. 1.035416667. PubMed
  164. Campesato LF, et al. 2020. Nat Commun. 3.24375. PubMed
  165. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  166. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  167. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  168. Apte S, et al. 2011. Int J Parasitol. 41:1285. PubMed
  169. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  170. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  171. Piñón-Zárate G, et al. 2022. Molecules. 27:. PubMed
  172. Sugita S, et al. 2013. Invest Ophthalmol Vis Sci . 54:3420. PubMed
  173. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  174. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  175. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  176. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  177. Zhou Y, et al. 2022. Front Oncol. 12:825783. PubMed
  178. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  179. Nakagawa Y, et al. 2015. Immunol Lett. 167: 72-86. PubMed
  180. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  181. Haile S, et al. 2011. J Immunol. 186:6822. PubMed
  182. Strait AA, et al. 2021. Commun Biol. 4:1005. PubMed
  183. Zheng Y, et al. 2022. Transl Res. :. PubMed
  184. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  185. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
  186. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  187. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  188. Sethuraman SN, et al. 2020. Theranostics. 10:3397. PubMed
  189. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  190. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  191. Zuo S, et al. 2021. EBioMedicine. 64:103240. PubMed
  192. Loptez-Albraitero A, et al. 2017. OncoImmunology. 10.1080/2162402X.2016.1267891. PubMed
RRID
AB_2073557 (BioLegend Cat. No. 124307)
AB_2073556 (BioLegend Cat. No. 124308)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 12/22/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account